Investigational icotrokinra is the first targeted oral peptide designed to selectively block the IL-23 receptor, 14 which underpins the inflammatory response in moderate-to-severe plaque PsO ...

Icotrokinra demonstrated high rates of clearance in scalp and genital psoriasis after 16 weeks of treatment, according to data presented at the 2025 Society for Investigative Dermatology Annual ...

NDA for icotrokinra for the treatment of adults and adolescents 12 years of age and older with moderate to severe plaque ...

Icotrokinra (JNJ-2113), a first-in-class investigational targeted oral peptide that selectively blocks the IL-23 receptor, met its co-primary endpoints in patients with moderate to severe plaque ...

In the adolescent subgroup, 84.1% of patients treated with icotrokinra achieved IGA scores of 0/1 and 70.5% achieved PASI 90, compared with 27.3% and 13.6% receiving placebo, respectively, at week 16.

Icotrokinra is uniquely designed to block the IL-23 receptor,which underpins the inflammatory response in plaque PsO and offers potential in other IL-23-mediated diseases. [1], [2], [3 ...

Icotrokinra led to high rates of skin clearance in patients with scalp and genital psoriasis, according to results from the ICONIC-TOTAL study. Icotrokinra is an investigational oral peptide that ...

Icotrokinra demonstrated a favorable safety profile, with 50% of adolescents treated with icotrokinra experienced ≥1 adverse event (AE), compared to 73% of adolescents receiving placebo at 16 weeks.

Icotrokinra demonstrated a favorable safety profile, with 50% of adolescents treated with icotrokinra experienced ≥1 adverse event (AE), compared to 73% of adolescents receiving placebo at 16 weeks.